Pilot study of a novel vacuum-assisted method for decellularization of tracheae for clinical tissue engineering applications

Pilot study of a novel vacuum-assisted method for decellularization of tracheae for clinical tissue engineering applications
复制标题

DOI:
10.1002/term.1979
复制
发表时间:
2017-03-01
影响因子:
3.3
通讯作者:
Ansari, T.
Ansari, T.
中科院分区:
工程技术3区
文献类型:
--
作者:
Lange, P.;Greco, K.;Ansari, T.

文献摘要

被引文献

相似文献

组织工程气管已成功地植入治疗少数病人的同情理由。由于生产支架所花费的时间和由此产生的财务成本,该治疗尚未成为主流。我们开发了一种基于真空技术的脱细胞(DC)方法,当与酶/洗涤剂方案结合时,可显著减少创建临床合适支架所需的时间。我们应用该技术制备了猪气管支架,并将结果与正常大气压下生产的支架进行了比较。主要结果测量是时间的减少(9天制备支架),随后是残留DNA水平的降低(DC无真空:137.8 +/-48.82 ng/mg vs. DC真空36.83 +/-18.45 ng/mg,p < 0.05)。我们的方法不影响胶原蛋白或糖胺聚糖含量或支架的生物力学性能。我们将真空技术应用于人体气管,当植入体内时,没有显示出明显的不良免疫反应。向常规脱细胞方案中添加真空显著减少了生产时间,同时提供了合适的支架。这增加了临床实用性并降低了生产成本。据我们所知,这是第一次探索真空辅助脱细胞。版权所有(C)2015约翰威利父子有限公司
Tissue engineered tracheae have been successfully implanted to treat a small number of patients on compassionate grounds. The treatment has not become mainstream due to the time taken to produce the scaffold and the resultant financial costs. We have developed a method for decellularization (DC) based on vacuum technology, which when combined with an enzyme/detergent protocol significantly reduces the time required to create clinically suitable scaffolds. We have applied this technology to prepare porcine tracheal scaffolds and compared the results to scaffolds produced under normal atmospheric pressures. The principal outcome measures were the reduction in time (9 days to prepare the scaffold) followed by a reduction in residual DNA levels (DC no-vac: 137.8 +/- 48.82 ng/mg vs. DC vac 36.83 +/- 18.45 ng/mg, p < 0.05.). Our approach did not impact on the collagen or glycosaminoglycan content or on the biomechanical properties of the scaffolds. We applied the vacuum technology to human tracheae, which, when implanted in vivo showed no significant adverse immunological response. The addition of a vacuum to a conventional decellularization protocol significantly reduces production time, whilst providing a suitable scaffold. This increases clinical utility and lowers production costs. To our knowledge this is the first time that vacuum assisted decellularization has been explored. Copyright (C) 2015 John Wiley & Sons, Ltd.